BioCurex, Inc.(fka BOCX)

[was Gyro]

Dakota,

There are also references in the filings. I think the list you are looking for is the third set below:

Cheers,
Gyro

******************************
http://www.sec.gov/Archives/edgar/data/1092562/000100487808000037/0001004878-08-000037.txt
5. PATENTS

Patents relate to developing the method for diagnostic and treatment of
cancer using a new cancer marker called "RECAF." These patents are presently
registered in 24 countries with ongoing registrations currently being
conducted. Patents are stated at cost and have a definite life.

******************************
http://www.sec.gov/Archives/edgar/data/1092562/000100487807000168/0001004878-07-000168.txt
Patents
- -------

Biocurex's technology is protected by a United States patent which expires
in 2014 and by patents in Australia, Russia, and China which expire in 2015.
Biocurex has also filed patent applications in Canada and six other foreign
countries.

******************************

http://www.sec.gov/Archives/edgar/data/1092562/000100487808000053/0001004878-08-000053-index.htm
Specifically, http://www.sec.gov/Archives/edgar/data/1092562/000100487808000053/sb2amnd3s12-08ex104.txt

   
     EXHIBIT 1.14 
     
                                      PATENT RIGHTS 
     
     
    U.S.               U.S.10/688,464 app, continuation of U.S. Patent 6,514,686 
    Russia             2161042 Patent 
    Finland            970990 app (identified in Inpadoc as 9700990) 
    Canada             2,197,490 app 
    Norway             19971256 app 
    EPO                95940906.1 app 
    China             200310104769.x app (identified in Inpadoc as 1132012), 
                      continuation of Patent 95195125.4 (identified in Inpadoc as 
                      1169778) 
    Japan             HEI. 8-510734 app (identified in Inpadoc as JP 11511847) 
    Brazil            PI 9508959-4 app 
    Australia        2003204325 app (identified in Inpadoc as 9537648 A1), 
                     continuation of 714966 Patent 
     
     
                                           33

*****************************